<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217477</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000441212</org_study_id>
    <nct_id>NCT00217477</nct_id>
  </id_info>
  <brief_title>Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer</brief_title>
  <official_title>An Open Label, Dose Escalation Study of Paricalcitol (Zemplar™) [19-NOR-1 ALPHA, 25-(OH) D] in Combination With Gemcitabine [2', 2' -Difluorodeoxycytidine] in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Paricalcitol may cause cancer cells to look more like normal cells, and to grow&#xD;
      and spread more slowly. Drugs used in chemotherapy, such as gemcitabine, work in different&#xD;
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving paricalcitol together with gemcitabine may be an effective treatment for&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of paricalcitol when&#xD;
      given together with gemcitabine in treating patients with advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of paricalcitol when given with gemcitabine&#xD;
           in patients with advanced malignancy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine safety and toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of these regimens in these patients.&#xD;
&#xD;
        -  Determine the clinical outcome (overall survival and best overall response) of patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, open-label study.&#xD;
&#xD;
      Patients receive gemcitabine IV over 80 minutes on days 1, 8, and 15 and paricalcitol IV over&#xD;
      15 minutes on days 7 and 14 in course 1. Beginning in course 2, patients receive paricalcitol&#xD;
      IV over 15 minutes on days 1, 8, and 15 and gemcitabine IV over 80 minutes on days 2, 9, and&#xD;
      16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of paricalcitol until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the&#xD;
      MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) of i. v. pancalcitol given weekly, in combination with fixed dose rate infusion of i. v.gemcitabine given weekly in patients with advanced malignancies.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess toxicity.</measure>
    <time_frame>8 week intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of paricalcitol on the pharmacokinetics of gemcitabine.</measure>
    <time_frame>Days 1 &amp; 8, cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of pariclcitol on cytidine deaminase in PBM</measure>
    <time_frame>Days 1 &amp; 8, cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of paricalcitol on dFdCTP in PBM</measure>
    <time_frame>Days 1 &amp; 8, cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetics of paricalcitol when given with gemcitabine</measure>
    <time_frame>Day 7, cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe clinical outcome for response and survival</measure>
    <time_frame>8 week intervals</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Paricalcitol IV in combination with Gemcitabine IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV over 80 minutes on days 1, 8, and 15 and paricalcitol IV over 15 minutes on days 7 and 14 in course 1. Beginning in course 2, patients receive paricalcitol IV over 15 minutes on days 1, 8, and 15 and gemcitabine hydrochloride IV over 80 minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Paricalcitol IV in combination with Gemcitabine IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Paricalcitol IV in combination with Gemcitabine IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of advanced malignancy&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
               -  Standard curative or palliative measures do not exist or are no longer effective&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
               -  Patients with previously treated brain metastases are eligible provided they have&#xD;
                  recovered from prior treatment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 3.0 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Corrected calcium ≤ 10.5 mg/dL&#xD;
&#xD;
          -  Prior single confirmed urolithiasis allowed provided patient is free of stone&#xD;
             formation for ≥ 5 years&#xD;
&#xD;
          -  No calculi in the urinary tract on kidney ultrasound biopsy or other imaging studies&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to study drugs&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Curative therapy for a condition associated with the risk of renal stones (e.g.,&#xD;
             hyperparathyroidism, bladder dysfunction, or obstructive uropathy) allowed provided&#xD;
             patients have been free of stone formation for ≥ 5 years&#xD;
&#xD;
          -  No concurrent digoxin&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renuka Iyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

